公开(公告)号：EP2862572B1

公开(公告)日：2018-11-28

申请号：EP13803699.1

申请日：2013-06-14

申请人： Foundation for Biomedical Research and Innovation at Kobe

发明人： IHARA, Masafumi ,  MAKI, Takakuni ,  TAGUCHI, Akihiko

IPC分类号： A61K31/4709 ,  A61K9/14 ,  A61P25/28

CPC分类号： A61K31/4709 ,  A61K9/0019 ,  A61K9/14 ,  C07D401/12

摘要： Provided is a prophylactic and/or therapeutic drug for mild cognitive impairment, which can improve interstitial flow in cerebral blood vessel and the like to achieve sufficient clearance of harmful proteins accumulated in the brain. The prophylactic and/or therapeutic drug includes 6-[4-(1-cyclohexyl-1H-tetrazole-5-yl)butoxy]3,4-dihydrocarbostyril or a salt thereof as an active ingredient. The prophylactic and/or therapeutic drug can improve a flow of interstitial fluid around blood vessels in a drainage pathway to excrete harmful proteins. The prophylactic and/or therapeutic drug for mild cognitive impairment may take the form of a pharmaceutical product for oral administration, a liquid pharmaceutical product for oral administration, or an injectable preparation. The prophylactic and/or therapeutic drug for mild cognitive impairment can be used for the prevention and/or treatment of cerebral amyloid angiopathy, and can also be used for improvement of Lewy body disease, Down's syndrome, or macular degeneration.

公开(公告)号：EP3763375A1

公开(公告)日：2021-01-13

申请号：EP19763545.1

申请日：2019-03-05

申请人： Foundation for Biomedical Research and Innovation at Kobe

发明人： TAGUCHI, Akihiko

IPC分类号： A61K35/28 ,  A61K35/15 ,  A61P1/00 ,  A61P1/18 ,  A61P3/10 ,  A61P9/00 ,  A61P9/04 ,  A61P9/10 ,  A61P11/00 ,  A61P13/12 ,  A61P25/00 ,  A61P25/28 ,  G01N33/15 ,  G01N33/48

摘要： The present invention provides a cell preparation in which a proportion of leukocyte in a normal form and an undesired component containing at least one selected from the group consisting of erythrocyte, deformed cell, platelet and aggregate (undesired component count/leukocyte count) is not more than a predetermined value. The aforementioned predetermined value is preferably 37.0%. In addition, the cell preparation of the present invention can be utilized for the treatment of ischemic diseases such as cerebral infarction, myocardial infarction, limb ischemia, renal infarction, pulmonary infarction, splenic infarction, the intestinal infarction, Buerger disease, cerebrovascular dementia, diabetic nephropathy microangiopathy, diabetic cardiac failure and the like.